Cognition Extends DLB Trial Access, Signals FDA Endpoint Discussion

Event summary

  • Cognition Therapeutics is extending its expanded access program (EAP) for Zervimesine (CT1812) in Dementia with Lewy Bodies (DLB), allowing participants additional treatment months beyond the initial 12-month plan.
  • The EAP, initiated in June 2025, currently involves 32 participants across eight clinical sites.
  • Cognition held a Type C meeting with the FDA on January 21, 2026, to discuss clinically meaningful endpoints for future DLB studies.
  • The company has implemented a strategy to reduce patient travel burden by enabling local physicians to conduct routine monitoring.

The big picture

Cognition's extension of the EAP and ongoing discussions with the FDA highlight the challenges in developing therapies for DLB, a complex and underserved neurological condition. The company's focus on patient-centric operational strategies, like decentralized monitoring, reflects a broader trend in clinical trials aimed at improving patient access and retention. The Type C meeting outcome will be a critical inflection point for the Zervimesine program and its potential to address a significant unmet medical need.

What we're watching

Regulatory Risk
The FDA’s feedback on clinically meaningful endpoints, expected in February, will be crucial in shaping the design of future DLB trials and could impact Zervimesine’s development pathway.
Efficacy Signals
The favorable feedback from EAP participants, while encouraging, needs to be rigorously assessed for genuine efficacy signals and not solely attributed to placebo or supportive care.
Operational Scalability
The success of the decentralized monitoring model implemented in the EAP will be a key factor in determining the feasibility of broader clinical trial implementation and patient recruitment.